Death-associated protein kinase 1 promotes growth of p53-mutant cancers.

Estrogen receptor-negative (ER-negative) breast cancers are extremely aggressive and associated with poor prognosis. In particular, effective treatment strategies are limited for patients diagnosed with triple receptor-negative breast cancer (TNBC), which also carries the worst prognosis of all forms of breast cancer; therefore, extensive studies have focused on the identification of molecularly targeted therapies for this tumor subtype. Here, we sought to identify molecular targets that are capable of suppressing tumorigenesis in TNBCs. Specifically, we found that death-associated protein kinase 1 (DAPK1) is essential for growth of p53-mutant cancers, which account for over 80% of TNBCs. Depletion or inhibition of DAPK1 suppressed growth of p53-mutant but not p53-WT breast cancer cells. Moreover, DAPK1 inhibition limited growth of other p53-mutant cancers, including pancreatic and ovarian cancers. DAPK1 mediated the disruption of the TSC1/TSC2 complex, resulting in activation of the mTOR pathway. Our studies demonstrated that high DAPK1 expression causes increased cancer cell growth and enhanced signaling through the mTOR/S6K pathway; evaluation of multiple breast cancer patient data sets revealed that high DAPK1 expression associates with worse outcomes in individuals with p53-mutant cancers. Together, our data support targeting DAPK1 as a potential therapeutic strategy for p53-mutant cancers.

[1]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[2]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[3]  S. Rho,et al.  DAPk1 inhibits NF-κB activation through TNF-α and INF-γ-induced apoptosis. , 2012, Cellular signalling.

[4]  A. Sivachenko,et al.  Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.

[5]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[6]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[7]  T. Hudson,et al.  The Genetic Basis for Cancer Treatment Decisions , 2012, Cell.

[8]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[9]  I. Shih,et al.  Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis , 2011, Modern Pathology.

[10]  G. Mills,et al.  Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. , 2010, The Journal of clinical investigation.

[11]  S. Hilsenbeck,et al.  Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. , 2009, Cancer research.

[12]  John Quackenbush,et al.  Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor–Negative Breast Cancer , 2009, Clinical Cancer Research.

[13]  O. Sansom,et al.  Peptide Combinatorial Libraries Identify TSC2 as a Death-associated Protein Kinase (DAPK) Death Domain-binding Protein and Reveal a Stimulatory Role for DAPK in mTORC1 Signaling* , 2009, Journal of Biological Chemistry.

[14]  B. Manning,et al.  The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. , 2008, The Biochemical journal.

[15]  T. Hupp,et al.  Novel insights into DAPK autophagic signalling using peptide aptamer combinatorial protein-interaction screens , 2008, Autophagy.

[16]  J. Bradley,et al.  TNF‐mediated inflammatory disease , 2008, The Journal of pathology.

[17]  J. Bergh,et al.  Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.

[18]  J. Blenis,et al.  RAS/ERK Signaling Promotes Site-specific Ribosomal Protein S6 Phosphorylation via RSK and Stimulates Cap-dependent Translation* , 2007, Journal of Biological Chemistry.

[19]  J. Fraser,et al.  Chemical genetics approach to identify peptide ligands that selectively stimulate DAPK-1 kinase activity. , 2007, Biochemistry.

[20]  J. Fraser,et al.  The MDM2 Ubiquitination Signal in the DNA-Binding Domain of p53 Forms a Docking Site for Calcium Calmodulin Kinase Superfamily Members , 2007, Molecular and Cellular Biology.

[21]  P. Gallagher,et al.  Control of Death-associated Protein Kinase (DAPK) Activity by Phosphorylation and Proteasomal Degradation* , 2006, Journal of Biological Chemistry.

[22]  S. Hilsenbeck,et al.  Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. , 2006, Cancer research.

[23]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[24]  C. Walker,et al.  Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning , 2006, The Journal of cell biology.

[25]  S. Gygi,et al.  The Tumor Suppressor DAP Kinase Is a Target of RSK-Mediated Survival Signaling , 2005, Current Biology.

[26]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Pelicci,et al.  dapk1, encoding an activator of a p19ARF-p53-mediated apoptotic checkpoint, is a transcription target of p53 , 2005, Oncogene.

[28]  P. Hall,et al.  An expression signature for p 53 status in human breast cancer predicts mutation status , transcriptional effects , and patient survival , 2005 .

[29]  Qiang Shen,et al.  AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity , 2004, Oncogene.

[30]  Steven P Gygi,et al.  Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. Børresen-Dale,et al.  TP53 and breast cancer , 2003, Human mutation.

[32]  Miriam Eisenstein,et al.  The DAP-kinase family of proteins: study of a novel group of calcium-regulated death-promoting kinases. , 2002, Biochimica et biophysica acta.

[33]  S. Hilsenbeck,et al.  Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth , 2002, Oncogene.

[34]  A. Kimchi,et al.  DAP kinase and DRP-1 mediate membrane blebbing and the formation of autophagic vesicles during programmed cell death , 2002, The Journal of cell biology.

[35]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[36]  Jia-Yun Chen,et al.  TGF-β induces apoptosis through Smad-mediated expression of DAP-kinase , 2002, Nature Cell Biology.

[37]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[38]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Kimchi,et al.  DAP kinase-a proapoptotic gene that functions as a tumor suppressor. , 2001, Experimental cell research.

[40]  Gustavo Droguett,et al.  DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation , 2000, Nature Cell Biology.

[41]  A. Kimchi,et al.  Dap-Kinase Participates in TNF-α–And FAS-Induced Apoptosis and Its Function Requires the Death Domain , 1999, The Journal of cell biology.

[42]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[43]  C. Moyret-Lalle,et al.  Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function , 1997, Oncogene.

[44]  Peter A. Jones,et al.  DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene , 1997, Oncogene.

[45]  A. Kimchi,et al.  DAP‐kinase is a Ca2+/calmodulin‐dependent, cytoskeletal‐associated protein kinase, with cell death‐inducing functions that depend on its catalytic activity , 1997, The EMBO journal.

[46]  A. Kimchi,et al.  Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. , 1995, Genes & development.

[47]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.